D-ID, the leading platform for the generation of digital humans, is transforming the landscape of digital content creation with the launch of Personal Avatars, comprising Premium+ Avatars and Express Avatars, the world’s highest-quality AI video-to-video avatar creation tools. Read...
Read MoreStellar Cyber partnering with NCSA enhances KKU’s cybersecurity teaching efficiency with new Open XDR platformLatest knowledge helps protect global cyber threats and strengthen the digital security landscape in Thailand Stellar Cyber, the innovator of Open XDR technology, announced its partnership with The National Cyber Security Agency of Thailand (NCSA) in providing the new Open XDR platform, under the Stellar Cyber University Program, to enable Khon Kaen University (KKU) free access to the Stellar Cyber’s advanced comprehensive detection and response platform. This collaboration is to add best-of-breed tools to KKU’s existing cybersecurity program and to accelerate the highly qualified cybersecurity graduates to meet the world demand. Read more...
Read MoreGUADALAJARA, MEXICO / ACCESSWIRE / October 30, 2024 / Kueski, the leading buy now, pay later (BNPL) and consumer lender in Latin America, has reached a significant milestone with 20 million loans distributed to Mexican consumers. This marks 100% growth in loans disbursed in just 18 months, further showcasing Kueski’s momentum as it moves forward in its mission to improve the financial lives of Mexicans. Read more...
Read MoreSAN FRANCISCO, Oct. 30, 2024 /PRNewswire/ — Corelight, the leader in open network detection and response (NDR) solutions, today announced it has been named to the Fortune Cyber 60 list, presented by Lightspeed, a listing of the most important venture-backed startups that offer enterprise-grade cybersecurity solutions. Corelight was added to the growth stage companies category and is the only company providing NDR solutions included on the list. Read...
Read MoreBOSTON–(BUSINESS WIRE)–Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms and services, today announced that it has entered into an institutional licensing agreement with Scripps Research for its ATX-Gx platform for fully human antibody discovery. The non-exclusive license enables all Scripps Research scientists to use the ATX-Gx platform for antibody drug and vaccine discovery workstreams. Scripps Research has been at the forefront of biomedical research since its founding in 1924, and its scientists have played pivotal roles in the development of more than 15 medicines approved by the U.S. Food and Drug Administration. Read...
Read More
